Skip to content

A prospective, multicenter, randomized, open clinical study to evaluate the efficacy and safety of different courses of high-dose amoxicillin combined with vonoprazan in the eradication of Helicobacter pylori

A prospective, multicenter, randomized, open clinical study to evaluate the efficacy and safety of different courses of high-dose amoxicillin combined with vonoprazan in the eradication of Helicobacter pylori

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059998
Enrollment
Unknown
Registered
2022-05-14
Start date
2022-05-16
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infecion

Interventions

A:amoxicillin (1000mg, three times A day) + vonolasan (20mg, twice A day) for 10 days.
B:amoxicillin (1000mg, three times a day) + vonolasan (20mg, twice a day) for 14 days

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Adult patients, aged 18 to 70 years; 2.Patients who did not take antibiotics, bismuth and traditional Chinese medicine 4 weeks before treatment, and patients who took PPI, H2 receptor antagonists and other drugs 2 weeks before treatment; 3.Hp-positive was diagnosed by C13 or C14-urea breath test and rapid urease test; 4.Informed and agreed to participate in the study, patients with complete medical records and follow-up records.

Exclusion criteria

Exclusion criteria: 1.With severe heart, lung, and kidney dysfunction and low immunity; 2.Patients with drug allergy contraindications; 3.Persons with mental illness or communication difficulties; 4.Pregnancy, lactation; 5.Patients with organic diseases such as gastrointestinal tumor and gastrointestinal hemorrhage.

Design outcomes

Primary

MeasureTime frame
eradication rate;

Secondary

MeasureTime frame
Degree of clinical symptom remission;adverse reaction;

Countries

China

Contacts

Public ContactZhihui Lin

Fujian Provincial Hospital

13799371368@qq.com+86 13799371368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026